Sultan Siddique, MD
Clinical Cardiac Electrophysiology · Columbia, SCNPI 1417995259
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $126,900 of the $182,423 with a category attached, or 69.6%. Boston Scientific accounts for 79.2% of it on its own, with 26 other manufacturers making up the rest. 2025 is the largest year on record at $100,852, 7.1 times the $14,297 reported in 2019.
Across 540 payments — averaging $337.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$145K
- Medtronic$14K
- Abbott$12K
- Pfizer$5K
- Medical Device Business Services, Inc.$3K
- E.r. Squibb & Sons, L.L.C.$771
- plus $3K from 21 others
Across 110 payments — averaging $1322.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$74K
- Boston Scientific$26K
- Microport CRM USA Inc$24K
- Biotronik Inc.$22K
What the payments were for
- Consulting fees$8,5755%
- Speaking & faculty fees$126,90070%
- Travel & lodging$29,52616%
- Food & beverage$17,41410%
- Education$80%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 231 | $144,544 |
| Medtronic(2 entities) | 99 | $13,631 |
| Abbott | 82 | $12,421 |
| Pfizer | 8 | $5,308 |
| Medical Device Business Services, Inc. | 15 | $2,932 |
| E.r. Squibb & Sons, L.L.C. | 16 | $771 |
| Biosense Webster, Inc. | 11 | $756 |
| Novartis | 26 | $551 |
| Atricure, Inc. | 10 | $428 |
| Impulse Dynamics (USA) Inc. | 3 | $204 |
| Johnson & Johnson | 7 | $127 |
| Philips North America LLC | 3 | $121 |
| Cardiva Medical, Inc. | 5 | $119 |
| Boehringer Ingelheim | 5 | $93 |
| Alnylam Pharmaceuticals Inc. | 3 | $61 |
| Convatec Inc. | 1 | $60 |
| Sanofi | 2 | $43 |
| Novo Nordisk | 2 | $42 |
| Cvrx, Inc. | 2 | $42 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $39 |
| Recor Medical Inc | 1 | $26 |
| Abiomed | 1 | $25 |
| Merck | 1 | $18 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Amgen | 1 | $14 |
| AstraZeneca | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL EP$92,500
- ELIQUIS$5,650
- Arctic Front$4,685
- ENSITE$4,569
- RHYTHMIA$3,615
- Farapulse$3,060
- Rhythmia Mapping System$2,869
- ENSITE PRECISION$2,802
- AMPLATZER AMULET$2,116
- Carto 3$1,710
- EVERA MRI XT DR SURESCAN$1,446
- Carto 3 System$1,244
- CardioInsight$1,038
- EMBLEM$998
- DiamondTemp$908
- WATCHMAN Access System$839
- DIAMONDTEMP BIDIRECTIONAL ABLATION CATHETER$779
- EnSite Precision Cardiac Mapping System$566
- NA$495
- Watchman$344
How this compares
$182,423 in reported general payments places this provider in the 85th percentile of 58 clinical cardiac electrophysiology providers in South Carolina.
See all clinical cardiac electrophysiology providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 15 | $14,667 |
| Digoxin | 11 | $50 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $5,308 | $14,66715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 58 clinical cardiac electrophysiology providers in South Carolina.
Other clinical cardiac electrophysiology in Columbia
- Walter MazzeiColumbia$96K
- Todd SennColumbia$49K
- Venkateshwar GottipatyColumbia$46K
- Francis UgoweColumbia$43K
- Jennifer FeldmanColumbia$19K
- Paras PatelColumbia$10K
- Gerald BauknightColumbia$10K
- Donald SiddowayColumbia$8K
- Hampton CollinsColumbia$22
- Jeffrey WinterfieldCharleston$498K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.